Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Website: nuvalent.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 5.0% (LTM)

Entry Point: Share price is 843.9% higher than minimum and 37.7% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders sold company shares on $9.2 mln (-0.193% of cap.)

Key Financials (Download financials)

Ticker: NUVL
Share price, USD:  (-2.4%)69.85
year average price 81.83  


year start price 65.48 2024-05-11

max close price 112.17 2024-09-16

min close price 59.32 2025-04-08

current price 69.85 2025-05-10
Common stocks: 64 605 308

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 4 513
Net Debt ($m): -658
EV (Enterprise Value): 3 855
Price to Book: 4.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-08prnewswire.com

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

2025-04-01prnewswire.com

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

2025-02-28prnewswire.com

Nuvalent to Participate in Upcoming March Investor Conferences

2025-02-27prnewswire.com

Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results

2025-01-13prnewswire.com

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

2025-01-10seekingalpha.com

Nuvalent: A Logical Acquisition Target

2024-12-19prnewswire.com

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

2024-11-26prnewswire.com

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

2024-11-12prnewswire.com

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

2024-09-23seekingalpha.com

Nuvalent: Promising Data Keeps Validating Pipeline And Platform
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-08 2024-05-09 2024-02-27 2023-11-14 2023-08-10 2023-05-11 2023-03-16 2022-11-10
acceptedDate 2024-11-12 06:42:31 2024-08-08 06:46:28 2024-05-09 06:46:09 2024-02-27 06:42:43 2023-11-14 06:50:42 2023-08-10 06:49:05 2023-05-11 06:44:40 2023-03-16 06:44:09 2022-11-10 07:01:27
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 0 0 0 0 0
grossProfit 0 0 0 0 0 0 0 0 0
grossProfitRatio 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 61M 49M 39M 36M 30M 26M 22M 23M 15M
generalAndAdministrativeExpenses 16M 16M 14M 11M 9M 8M 8M 6M 6M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 16M 16M 14M 11M 9M 8M 8M 6M 6M
otherExpenses 0 0 0 -5M 0 0 5M 3M 0
operatingExpenses 76M 65M 53M 46M 39M 34M 30M 29M 20M
costAndExpenses 76M 65M 53M 46M 39M 34M 30M 29M 20M
interestIncome 9M 8M 8M 8M 5M 5M 0 3M 0
interestExpense 0 0 8M 18M 5M 5M -5M 3M -672 000
depreciationAndAmortization 0 0 53M 43 812 0 0 0 -2M 0
ebitda -76M -65M -53M -46M -39M -34M -30M -29M -20M
ebitdaratio 0 0 0 0 0 0 0 0 0
operatingIncome -76M -65M -53M -46M -39M -34M -30M -29M -20M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet -8M 8M 8M 8M 5M 5M 5M 3M 672 000
incomeBeforeTax -84M -57M -44M -38M -34M -29M -25M -26M -20M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0
incomeTaxExpense 40 000 170 000 -383 000 5M 0 0 -5M -6M -672 000
netIncome -84M -57M -44M -38M -34M -29M -20M -20M -19M
netIncomeRatio 0 0 0 0 0 0 0 0 0
eps -1.28 -0.88 -0.69 -0.62 -0.59 -0.51 -0.36 -0.37 -0.39
epsdiluted -1.28 -0.88 -0.69 -0.62 -0.59 -0.51 -0.36 -0.37 -0.39
weightedAverageShsOut 66M 65M 64M 62M 57M 57M 57M 54M 48M
weightedAverageShsOutDil 66M 65M 64M 62M 57M 57M 57M 54M 48M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-08 2024-05-09 2024-02-27 2023-11-14 2023-08-10 2023-05-11 2023-03-16 2022-11-10
acceptedDate 2024-11-12 06:42:31 2024-08-08 06:46:28 2024-05-09 06:46:09 2024-02-27 06:42:43 2023-11-14 06:50:42 2023-08-10 06:49:05 2023-05-11 06:44:40 2023-03-16 06:44:09 2022-11-10 07:01:27
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 369M 78M 99M 335M 88M 71M 90M 242M 76M
shortTermInvestments 799M 580M 593M 385M 325M 360M 360M 230M 164M
cashAndShortTermInvestments 1 168M 658M 692M 720M 413M 431M 450M 472M 240M
netReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
otherCurrentAssets 11M 8M 8M 7M 7M 6M 6M 6M 5M
totalCurrentAssets 1 180M 666M 699M 726M 420M 437M 456M 478M 245M
propertyPlantEquipmentNet 0 0 0 0 0 0 0 0 0
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 9M 9M 9M 6M 5M 5M 5M 4M 4M
totalNonCurrentAssets 9M 9M 9M 6M 5M 5M 5M 4M 4M
otherAssets 0 0 0 1 0 0 0 0 0
totalAssets 1 189M 675M 708M 732M 425M 442M 461M 482M 250M
accountPayables 16M 7M 13M 9M 10M 8M 6M 7M 5M
shortTermDebt 0 0 0 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 35M 31M 20M 23M 19M 13M 11M 12M 8M
totalCurrentLiabilities 51M 38M 33M 32M 29M 21M 17M 19M 13M
longTermDebt 0 0 0 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 17M 0 0 0 0 0 6M 7M -5M
totalNonCurrentLiabilities 17M 0 0 0 0 0 6M 7M 5M
otherLiabilities 0 0 0 0 0 0 -6M -7M -5M
capitalLeaseObligations 0 0 0 0 0 0 0 0 0
totalLiabilities 68M 38M 33M 32M 29M 21M 17M 19M 13M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 8000 7000 7000 7000 6000 6000 6000 6000 5000
retainedEarnings -472M -388M -331M -286M -248M -214M -185M -160M -134M
accumulatedOtherComprehensiveIncomeLoss 1M -2M -1M 31 000 -1M -2M -302 000 -494 000 -866 000
othertotalStockholdersEquity 1 592M 1 027M 1 007M 987M 645M 637M 630M 624M 371M
totalStockholdersEquity 1 121M 637M 675M 701M 396M 421M 444M 463M 237M
totalEquity 1 121M 637M 675M 701M 396M 421M 444M 463M 237M
totalLiabilitiesAndStockholdersEquity 1 189M 675M 708M 732M 425M 442M 461M 482M 250M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 189M 675M 708M 732M 425M 442M 461M 482M 250M
totalInvestments 799M 580M 593M 385M 325M 360M 360M 230M 164M
totalDebt 0 0 0 0 0 0 0 0 0
netDebt -369M -78M -99M -335M -88M -71M -90M -242M -76M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-08 2024-05-09 2024-02-27 2023-11-14 2023-08-10 2023-05-11 2023-03-16 2022-11-10
acceptedDate 2024-11-12 06:42:31 2024-08-08 06:46:28 2024-05-09 06:46:09 2024-02-27 06:42:43 2023-11-14 06:50:42 2023-08-10 06:49:05 2023-05-11 06:44:40 2023-03-16 06:44:09 2022-11-10 07:01:27
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -84M -57M -44M -38M -34M -29M -25M -26M -20M
depreciationAndAmortization 0 0 0 3M 0 0 -3M -836 000 0
deferredIncomeTax 0 0 0 4M 0 0 0 0 0
stockBasedCompensation 15M 0 14M 7M 7M 6M 5M 3M 3M
changeInWorkingCapital -2M 4M -2M 3M 6M 4M -2M 6M -1M
accountsReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables 8M -6M 4M -507 000 2M 2M -672 000 2M 592 000
otherWorkingCapital -11M 10M -6M 3M 5M 2M 672 000 4M -2M
otherNonCashItems 25M 12M 6M -2M -3M -3M 0 3000 -3000
netCashProvidedByOperatingActivities -46M -41M -36M -30M -23M -22M -24M -18M -18M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 0 0
acquisitionsNet 0 0 0 0 0 0 0 0 0
purchasesOfInvestments -341M -89M -283M -167M -23M -82M -188M -163M -20M
salesMaturitiesOfInvestments 128M 105M 76M 110M 62M 83M 61M 97M 37M
otherInvestingActivites 0 -1 -207M -56 261 38 400 0 0 0 0
netCashUsedForInvestingActivites -213M 16M -207M -56M 38M 2M -127M -65M 18M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 550M 4M 6M 334M 1M 2M 619 000 249M 0
commonStockRepurchased 0 0 0 387 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -188 000 -156 000 -466 000 333M 755 000 -364 000 -636 000 43 000 1M
netCashUsedProvidedByFinancingActivities 550M 4M 6M 333M 2M 1M -17 000 249M 1M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash 292M -21M -237M 247M 18M -19M -152M 165M 398 000
cashAtEndOfPeriod 369M 78M 99M 335M 88M 71M 90M 242M 76M
cashAtBeginningOfPeriod 78M 99M 335M 88M 71M 90M 242M 76M 76M
operatingCashFlow -46M -41M -36M -30M -23M -22M -24M -18M -18M
capitalExpenditure 0 0 0 0 0 0 0 0 0
freeCashFlow -46M -41M -36M -30M -23M -22M -24M -18M -18M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-11-12 11:30 ET
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
2024-10-28 13:29 ET
From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
2024-09-18 20:05 ET
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
2024-09-17 02:23 ET
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
2024-09-16 11:00 ET
Nuvalent Announces Public Offering of Common Stock
2024-09-14 09:00 ET
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
2024-09-09 10:30 ET
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
2024-08-29 10:30 ET
Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-07-22 10:30 ET
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
2024-07-16 10:30 ET
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
2024-07-11 10:30 ET
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
2024-05-29 10:30 ET
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
2024-05-16 20:01 ET
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
2024-05-09 10:30 ET
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
2024-04-08 20:30 ET
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
2024-03-05 21:52 ET
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
2024-02-27 11:30 ET
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 11:15 ET
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
2024-02-12 11:30 ET
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
2024-02-01 11:30 ET
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2024-01-08 11:30 ET
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
2023-12-21 11:30 ET
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-14 11:30 ET
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
2023-11-01 10:30 ET
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day
2023-10-16 11:30 ET
Nuvalent Announces Public Offering of Common Stock
2023-10-13 10:30 ET
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC
2023-10-04 16:21 ET
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile
2023-09-18 10:30 ET
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
2023-09-05 10:30 ET
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
2023-08-31 10:30 ET
Nuvalent to Participate in Upcoming September Investor Conferences
2023-08-10 10:30 ET
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
2023-08-01 10:30 ET
Nuvalent to Participate in Upcoming August Investor Conferences
2023-05-24 10:30 ET
Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
2023-05-11 10:30 ET
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
2023-04-19 10:30 ET
Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days
2023-04-18 13:00 ET
Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023
2023-03-23 10:30 ET
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
2023-03-16 10:30 ET
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
2023-03-14 21:59 ET
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023
2023-03-01 11:30 ET
Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference
2023-01-04 11:30 ET
Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-13 15:15 ET
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520
2022-11-10 11:30 ET
Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
2022-11-04 00:13 ET
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
2022-10-31 11:15 ET
Nuvalent Announces Public Offering of Common Stock
2022-10-28 04:01 ET
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC
2022-10-26 10:30 ET
Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655
2022-10-17 10:30 ET
Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium
2022-10-06 10:30 ET
Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors
2022-09-07 10:30 ET
Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates
2022-09-01 10:30 ET
Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference
2022-08-10 10:30 ET
Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results
2022-08-05 10:30 ET
Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
2022-08-03 10:30 ET
Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference
2022-07-20 10:30 ET
Nuvalent Announces Leadership Promotions
2022-07-13 10:30 ET
Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
2022-06-21 10:30 ET
Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers
2022-06-02 10:38 ET
Nuvalent to Present at the 2022 Jefferies Healthcare Conference
2022-05-12 10:30 ET
Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results
2022-04-08 17:15 ET
Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
2022-04-07 10:30 ET
Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference
2022-03-31 10:30 ET
Nuvalent Appoints Anna Protopapas as Chair of Board of Directors
2022-03-29 10:30 ET
Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
2022-03-08 22:38 ET
Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
2022-03-02 11:30 ET
Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference
2022-02-03 11:30 ET
Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors
2022-01-07 11:30 ET
Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor
2022-01-04 11:30 ET
Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-11-10 11:30 ET
Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results
2021-10-07 13:21 ET
New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC
2021-09-08 10:30 ET
Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
2021-08-02 21:39 ET
Nuvalent Announces Closing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2025-05-08 11:42 ET
Nuvalent, Inc. reported for 2025 q1
SEC form 8
2025-05-08 11:36 ET
Nuvalent, Inc. reported for 2025 q1
SEC form 8
2025-05-08 11:36 ET
Nuvalent, Inc. published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Nuvalent, Inc. reported for 2025 q1
SEC form 10
2025-02-27 00:00 ET
Nuvalent, Inc. reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Nuvalent, Inc. reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Nuvalent, Inc. published news for 2024 q4
SEC form 10
2024-11-12 06:42 ET
Nuvalent, Inc. reported for 2024 q3
SEC form 8
2024-11-12 06:38 ET
Nuvalent, Inc. published news for 2024 q3
SEC form 8
2024-11-12 06:38 ET
Nuvalent, Inc. reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Nuvalent, Inc. reported for 2024 q3
SEC form 10
2024-08-08 06:46 ET
Nuvalent, Inc. reported for 2024 q2
SEC form 8
2024-08-08 06:41 ET
Nuvalent, Inc. published news for 2024 q2
SEC form 8
2024-08-08 06:41 ET
Nuvalent, Inc. published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Nuvalent, Inc. published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Nuvalent, Inc. reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Nuvalent, Inc. published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Nuvalent, Inc. published news for 2024 q1
SEC form 10
2024-02-27 06:42 ET
Nuvalent, Inc. published news for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Nuvalent, Inc. published news for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Nuvalent, Inc. published news for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Nuvalent, Inc. reported for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Nuvalent, Inc. published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Nuvalent, Inc. published news for 2023 q4
SEC form 10
2023-11-14 06:50 ET
Nuvalent, Inc. reported for 2023 q3
SEC form 8
2023-11-14 06:45 ET
Nuvalent, Inc. reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Nuvalent, Inc. reported for 2023 q3
SEC form 10
2023-08-10 06:49 ET
Nuvalent, Inc. reported for 2023 q2
SEC form 6
2023-08-10 06:45 ET
Nuvalent, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Nuvalent, Inc. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Nuvalent, Inc. reported for 2023 q2
SEC form 6
2023-06-16 18:46 ET
Nuvalent, Inc. published news for 2023 q1
SEC form 6
2023-06-16 16:08 ET
Nuvalent, Inc. published news for 2023 q1
SEC form 10
2023-05-11 06:44 ET
Nuvalent, Inc. reported for 2023 q1
SEC form 6
2023-05-11 06:39 ET
Nuvalent, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Nuvalent, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Nuvalent, Inc. reported for 2023 q1
SEC form 6
2023-04-28 16:13 ET
Nuvalent, Inc. published news for 2023 q1
SEC form 6
2023-04-13 16:30 ET
Nuvalent, Inc. published news for 2023 q1
SEC form 10
2023-03-16 06:44 ET
Nuvalent, Inc. reported for 2022 q4
SEC form 6
2023-03-16 06:36 ET
Nuvalent, Inc. reported for 2022 q4
SEC form 10
2023-03-16 00:00 ET
Nuvalent, Inc. reported for 2022 q4
SEC form 8
2023-03-16 00:00 ET
Nuvalent, Inc. reported for 2022 q4
SEC form 6
2023-03-10 20:38 ET
Nuvalent, Inc. published news for 2022 q4
SEC form 10
2022-11-10 07:01 ET
Nuvalent, Inc. reported for 2022 q3
SEC form 6
2022-11-10 06:37 ET
Nuvalent, Inc. reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Nuvalent, Inc. reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Nuvalent, Inc. reported for 2022 q3
SEC form 6
2022-11-07 18:24 ET
Nuvalent, Inc. published news for 2022 q3
SEC form 6
2022-11-01 17:19 ET
Nuvalent, Inc. published news for 2022 q3
SEC form 6
2022-10-28 06:05 ET
Nuvalent, Inc. published news for 2022 q3
SEC form 6
2022-10-06 16:16 ET
Nuvalent, Inc. published news for 2022 q3
SEC form 10
2022-08-10 07:08 ET
Nuvalent, Inc. reported for 2022 q2
SEC form 6
2022-08-10 06:39 ET
Nuvalent, Inc. reported for 2022 q2
SEC form 8
2022-08-10 00:00 ET
Nuvalent, Inc. reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Nuvalent, Inc. reported for 2022 q2
SEC form 6
2022-06-21 16:30 ET
Nuvalent, Inc. published news for 2022 q1
SEC form 6
2022-06-21 16:14 ET
Nuvalent, Inc. published news for 2022 q1
SEC form 6
2022-05-19 16:36 ET
Nuvalent, Inc. published news for 2022 q1
SEC form 10
2022-05-12 06:52 ET
Nuvalent, Inc. reported for 2022 q1
SEC form 6
2022-05-12 06:45 ET
Nuvalent, Inc. published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Nuvalent, Inc. reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Nuvalent, Inc. reported for 2022 q1
SEC form 6
2022-04-29 16:07 ET
Nuvalent, Inc. published news for 2022 q1
SEC form 6
2022-03-31 07:07 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 6
2022-03-31 06:48 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 10
2022-03-29 07:21 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 6
2022-03-29 06:58 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 10
2022-03-29 00:00 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 8
2022-03-29 00:00 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 6
2022-02-03 16:41 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 6
2022-02-03 06:46 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 6
2022-01-07 06:40 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 8
2022-01-07 00:00 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 10
2021-11-10 06:49 ET
Nuvalent, Inc. published news for 2021 q3
SEC form 6
2021-11-10 06:44 ET
Nuvalent, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Nuvalent, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Nuvalent, Inc. published news for 2021 q3
SEC form 10
2021-09-08 08:31 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-09-08 06:35 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 10
2021-09-08 00:00 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-08-04 18:05 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-08-02 16:06 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-30 17:27 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:42 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:42 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:38 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:36 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:35 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:34 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:34 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:33 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:33 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:31 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:30 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 18:58 ET
Nuvalent, Inc. published news for 2021 q2